Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

Prokop Vodicka, Andrea Janikova, David Belada, Heidi Mocikova, Vit Prochazka, Juraj Duras, Katerina Steinerova, Vit Campr, Katerina Benesova, Samuel Hricko, Alice Sykorova, Petra Blahovcova, Radek Jaksa, Magdalena Klanova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2023-185620

Published: 2023

Journal Articles

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Heidi Mocikova, Andrea Janikova, Alice Sykorova, Vit Prochazka, Jan Pirnos, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Robert Pytlik, Petra Blahovcova, David Salek, Tomas Kozak, Veronika Bachanova, David Belada

Blood (2023) 142 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2023-180155

Published: 2023

Journal Articles

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4442.

https://doi.org/10.1182/blood-2023-186800

Published: 2023

Journal Articles

Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL)

Blood (2023) 142 (Supplement 1): 6542.

https://doi.org/10.1182/blood-2023-181249

Published: 2023

Journal Articles

Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy

Kamila Polgarova, Andrea Janíková, David Belada, Vit Prochazka, Juraj Ďuraš, Heidi Móciková, Kateřina Steinerová, Vít Campr, Petra Blahovcová, David Zogala, Václav Ptáčník, Marek Trneny

Blood (2022) 140 (Supplement 1): 3831–3832.

https://doi.org/10.1182/blood-2022-163113

Published: 2022

Journal Articles

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 2292–2295.

https://doi.org/10.1182/blood-2022-157194

Published: 2022

Journal Articles

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Heidi Mocikova, Jan Pirnos, Vit Prochazka, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Petra Blahovcova, Vit Campr, Pavel Klener, Jr., Alice Sykorova, Marek Trneny

Blood (2022) 140 (Supplement 1): 3775–3776.

https://doi.org/10.1182/blood-2022-159408

Published: 2022

Journal Articles

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Blood (2022) 140 (17): 1907–1916.

https://doi.org/10.1182/blood.2022015560

Published: 2022

Includes: Supplemental data

Journal Articles

Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group

Aleš Obr, Pavel Klener, Jr., Andrea Janíková, Heidi Mocikova, David Belada, David Šálek, Alice Sýkorová, Andrea Jirkuvová, Tomáš Papajík, Marek Trněný

Blood (2021) 138 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2021-146589

Published: 2021

Journal Articles

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Heidi Mocikova, Jana Markova, Lubica Gaherova, Maria Maco, Alice Sykorova, David Belada, Marie Lukasova, Vit K Prochazka, Katarina Hradska, Juraj Ďuraš, Ondrej Havranek, Tomas Kozak

Blood (2021) 138 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2021-148363

Published: 2021

Journal Articles

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Vít K Procházka, Štěpánka Matuštíková, Tomáš Fürst, Dr., David Belada, MD PhD, Andrea Janíková, MD PhD Assoc Prof, Kateřina Benešová, MD PhD, Heidi Mociková, MD, Juraj Ďuraš, MD, Jan Pirnos, MD, Kateřina Kopečková, MD PhD, Vít Campr, MD PhD, Jozef Michalka, MD, Robert Pytlík, MD, Tomáš Papajík, MD prof, Marek Trněný, MD prof

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139830

Published: 2020

Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3983.

https://doi.org/10.1182/blood-2019-129756

Published: 2019

Journal Articles

The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Pavel Otahal, MD PhD, Andrea Janikova, MD PhD Assoc Prof, David Belada, MD PhD, Vit Prochazka, MD, Heidi Mocikova, MD PhD, Jan Pirnos, Juraj Ďuraš, Kateřina Kopečková, Vit Campr, MD PhD, Robert Pytlik, Petra Blahovcova, Mgr, Marek Trneny, MD CSc

Blood (2018) 132 (Supplement 1): 5413.

https://doi.org/10.1182/blood-2018-99-117110

Published: 2018

Journal Articles

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

Blood (2018) 132 (22): 2389–2400.

https://doi.org/10.1182/blood-2018-06-855502

Published: 2018

Includes: Supplemental data

Journal Articles

Elderly Hodgkin Lymphoma - Multicenter Retrospective Data Analysis from the Czech Hodgkin Lymphoma Registry

Alice Sýkorová, MD PhD, Heidi Mocikova, MD PhD, Vit Prochazka, MD PhD Assoc Prof, Marie Lukasova, MD, Pavla Stepankova, MD, David Belada, MD PhD, Katerina Klaskova, MA, Lubica Gaherova, MD, Karel Chroust, MA, PhD, Jana Markova, MD

Blood (2017) 130 (Supplement 1): 2792.

https://doi.org/10.1182/blood.V130.Suppl_1.2792.2792

Published: 2017

Journal Articles

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Aleš Obr, MD, Vit Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD PhD prof., Pavel Klener, Jr., MD PhD Assoc Prof, Andrea Janikova, MD PhD Assoc Prof, David Salek, MD PhD, David Belada, MD PhD, Robert Pytlik, Alice Sýkorová, MD PhD, Heidi Mocikova, MD PhD, Martin Simkovic, MD PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 1498.

https://doi.org/10.1182/blood.V130.Suppl_1.1498.1498

Published: 2017

Journal Articles

Comparison of 2 Doses of Intravenous (IV) Temsirolimus (Temsr) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Wojciech Jurczak, MD, Sundra Ramanathan, MBBS FRCPA FRACP, Pratyush Giri, MBBS, FRACP, FRCPA, Francesco Di Raimondo, MD, Heidi Mocikova, MD, PhD, Jill Clancy, Mariajose Lechuga, MD, Michelle Casey, PhD, Joseph P Boni, PhD, Agnieszka Giza, MD, Georg Hess, MD

Blood (2016) 128 (22): 1775.

https://doi.org/10.1182/blood.V128.22.1775.1775

Published: 2016

Journal Articles

Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy

Vit K Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD prof., Andrea Janikova, MD PhD, Assoc Prof, David Belada, Tomas Kozak, MD, PhD, Prof., David Salek, MD PhD, Alice Sykorova, MD PhD, Heidi Mocikova, MD, PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trneny

Blood (2016) 128 (22): 1779.

https://doi.org/10.1182/blood.V128.22.1779.1779

Published: 2016

Journal Articles

Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry

Andrea Janikova, MD PhD, Assoc Prof, Robert Pytlik, MD, Pavel Klener, MD PhD, Zbynek Bortlicek, PhD, Vit Campr, MD PhD, Natasa Kopalova, Mgr, Katerina Benesova, MD PhD, Michaela Hamouzova, David Belada, MDPhD, Vit Prochazka, MD PhD ass. prof., Jan Pirnos, MD, Juraj Duras, MD, Heidi Mocikova, MD, PhD, Jiri Mayer, MD, Marek Trneny

Blood (2016) 128 (22): 3000.

https://doi.org/10.1182/blood.V128.22.3000.3000

Published: 2016

Journal Articles

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Heidi Mocikova, MD, PhD, Jana Markova, MD, Lubica Gaherova, MD, Lukas Smolej, MD, PhD, Assoc.Prof., Martin Simkovic, MD, Tomas Kozak, MD, PhD, Prof.

Blood (2015) 126 (23): 5298.

https://doi.org/10.1182/blood.V126.23.5298.5298

Published: 2015

NARROW

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL)

Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

Elderly Hodgkin Lymphoma - Multicenter Retrospective Data Analysis from the Czech Hodgkin Lymphoma Registry

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Comparison of 2 Doses of Intravenous (IV) Temsirolimus (Temsr) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy

Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only